You searched for "diabetes"
Comparing femtosecond laser assisted-DMEK to manual DMEK
Femtosecond laser is as a novel tool for performing precise descemetorhexis in descemet membrane endothelial keratoplasty (DMEK) surgery. In DMEK surgery, the recipient’s Descemet membrane is peeled to allow adherence of the donor DMEK tissue to the recipient’s stroma. Complete...Diabetic Retinopathy Network laser training programme
5 February 2020
| Nick Astbury, Denise Mabey, Joachim Kilemile, William Makupa, Marcia Zondervan
|
EYE - Vitreo-Retinal, EYE - General
The VISION 2020 Diabetic Retinopathy Network (DR-NET) was established in 2014 to tackle the increasing burden of diabetes and diabetic retinopathy (DR) in developing countries [1]. By forming a network of long-term LINK capacity-building partnerships, learning and best practice can...
A paradigm shift in the way we approach cataract surgery
Cataract surgery is the most common elective surgical procedure in the UK [1], with in the region of 350,000 cases being conducted each year. With an ageing population, this figure will only continue to rise over time. Cataract surgery is...Moorfields Education: Implementing a non-medical intravitreal injection service (19 May)
19 May 2023
This course is for clinicians working in an ophthalmic or medical retina setting, focusing on the treatment of age-related macular degeneration, retinal vein occlusion and diabetic oedema.
.
Aflibercept, bevacizumab or ranibizumab for DMO
1 August 2016
| Brian Ang
|
EYE - Vitreo-Retinal
This is a two-year randomised clinical trial of 660 patients with visual acuity impairment from diabetic macular oedema (DMO) who were randomised to monthly injections of 2.0mg aflibercept, 1.25 mg bevacizumab or 0.3mg ranibizumab. Focal or grid laser was performed...
Macular oedema after cataract surgery in diabetic patients
1 December 2013
| Lorraine North
|
EYE - Vitreo-Retinal
The authors describe a multi-centre prospective observational study of 293 participants that underwent cataract surgery who all had diabetic retinopathy without definite central-involved macular oedema. Forty-five clinical sites took part throughout the United States. Patients were eligible if there was...
Control of bleeding with diabetic vitrectomy under air
1 August 2019
| Kurt Spiteri Cornish
|
EYE - Vitreo-Retinal
The authors describe a modified diabetic vitrectomy using continuous air infusion in diabetic eyes with severe fibrovascular proliferation. In their case series of 25 eyes (20 patients), intravitreal bevacizumab (1.25mg) was used one week prior to surgery. Fifteen eyes had...
Intravitreal bevacizumab vs. triamcinolone in patients with DMO at the time of cataract surgery
1 October 2016
| Anjali Gupta
|
EYE - Vitreo-Retinal
This prospective, single masked randomised control trial (RCT) compared visual and anatomical outcomes when either intravitreal bevacizumab (BVB) or triamcinolone (TA) was administered at the time of cataract surgery and at subsequent review, if required, in patients with diabetic macula...
Aflibercept, bevacizumab or ranibizumab for diabetic macular oedema
1 April 2015
| Jonathan CP Roos
|
EYE - Vitreo-Retinal
Macular oedema (MO) is a leading cause of visual impairment in patients with diabetic retinopathy. Whilst laser photocoagulation therapy has been the proven treatment for decades, studies over the last five years have also established a role for anti-VEGF agents...
Prognostic information for PRP-naive patients
1 February 2015
| Saruban Pasu
|
EYE - Vitreo-Retinal
The Diabetic Retinopathy Study group demonstrated that pan retinal laser photocoagulation (PRP) reduces severe vision loss by up to 50% in cases of proliferative diabetic retinopathy (PDR). The authors of this current study aimed to provide information for laser naive...
Considerations in the management of retinal disorders
1 October 2017
| Rod McNeil
|
EYE - Vitreo-Retinal
Vision research presentations and publications explore practice considerations in the management of AMD and diabetic retinopathy. Over the past two decades in Europe there has been a decreasing prevalence of age-related macular degeneration (AMD) and an improvement in visual acuity...
Inherited retinal disorders now the leading cause of blindness
1 April 2014
| Thomas O'Neill
|
EYE - Vitreo-Retinal
The recent paper in BMJ Open, from the UCL Institute of Ophthalmology, ‘A comparison of the causes of blindness certifications in England and Wales in working age adults (16-64 years), 1999-2000 with 2009-2010’ concludes that inherited retinal disorders (IRD) such...